The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter

• Status: Enrolling by invitation
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utilizing 4% sodium citrate vs. heparin as a lock solution in central venous hemodialysis catheter among hemodialysis patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chang Gung Memorial Hospital
• Treatments: Citric Acid; Sodium Citrate

Criteria

Inclusion Criteria:

1. Age >=20 years

2. End-stage renal disease patients who received regular HD weekly via central venous catheter for at least 3 months in outpatient clinic in Kaohsiung Chang Gung Memorial Hospital, Taiwan

Exclusion Criteria:

1. bleeding tendency

2. on radiotherapy or chemotherapy for malignancy

3. pregnancy

4. drug allergy history to citrate

5. undefined reasons for refuted participation.